OPEN END TURBO OPTIONSSCHEIN SHORT - ELI LILLY & CO | Real-time BOERSE MUENCHEN 04:27:12 2024-07-17 am EDT | ||
| 18.21 EUR | +11.24% |
|
| Current month | -16.35% | ||
| 1 month | -28.08% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-17 | 18.21 | +11.24% |
| 24-07-16 | 16.37 | +4.73% |
| 24-07-15 | 15.63 | -2.74% |
| 24-07-12 | 16.07 | -9.82% |
| 24-07-11 | 17.82 | +5.76% |
Real-time BOERSE MUENCHEN
Last update July 17, 2024 at 04:27 am EDT
More quotesStatic data
| Product type | Warrant Knock-Out senza Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | Goldman Sachs |
| WKN | GQ7H7N |
| ISIN | DE000GQ7H7N1 |
| Date issued | 2023-10-13 |
| Strike | 1,123 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 48.2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 53.94 € |
|---|---|
| Lowest since issue | 14.66 € |
| Spread | 0.1 € |
| Spread % | 0.53% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
941.6
USD
Average target price
901.5
USD
Spread / Average Target
-4.26%
- Stock Market
- Certificates
- Certificat
